Oncology Pharma Inc.
20.7.2021 13:32:38 CEST | ACCESS Newswire | Press release
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with MCT as it most closely represents the setting of a human clinical trial.
Human preclinical methods are different as they use a small number of models with a large number of tests per subject. Mouse clinical trials tend to upend the traditional preclinical paradigm and better resemble and match the actual clinical setting. The Company believes this is an effective and cost-efficient way of moving forward. Utilizing MCTs will develop data that can be leveraged for biomarker discovery, which is ever more crucial for clinical trial success.
In addition, the Company continues to develop its business model to support the currently licensed IP and providing them with the necessary tools each individual licensor needs to support their individual business so they can contribute to the business plan of Oncology Pharma, Inc.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/656221/Oncology-Pharma-Inc-To-Move-to-Conducting-Trials-on-Licensed-IP
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Launches MetalPro(TM) Direct-to-Metal Hydrophilic Coatings for Medical Devices30.10.2026 14:37:00 CET | Press release
HORSHAM, PA / ACCESS Newswire / October 30, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego the launch of MetalPro™ direct-to-metal UV cure hydrophilic coatings engineered to bond directly to metal surfaces without primers or tie-layers. By eliminating additional tie-layers, MetalPro simplifies coating applications, reduces process complexity and has the potential to lower overall coating costs. The direct-to-metal approach also provides manufacturers with greater design flexibility, particularly for complex catheter systems where coating thickness and mechanical performance are important considerations. "Medical device engineers are continually challenged to improve device performance while simplifying manufacturing and managing costs," said Bob Hergenrother, PhD, Vice President of R&D and Innovation a
Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders30.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 30, 2026 / Chervon launches Advanced Momentum Program (AMP), reporting to Matt DeFeo, Senior Vice President, Sales, Training, and Recruiting. Chervon will be hiring hundreds of college graduates in the months and years ahead to deliver the company's aggressive growth strategy. The new AMP initiative was developed to catalyze Chervon's recruiting, training, development, promoting, and mentoring of the very best high-potential college grads. AMP will develop the next generation of Chervon leaders. The program features a comprehensive product, skills, and career development training system. AMP will recruit, develop and promote high-potential new hires into a broad range of positions including store coverage, end-user marketing, sales, product management, e-commerce/digital marketing, channel management, commercialization, service, engineering, supply chain, operations, and finance. Ultimately AMP will produce a stream of outstanding senior execu
Aehr Test Systems Appoints Former Meta Infrastructure Executive Vijay Rao to Board of Directors29.10.2026 12:30:00 CET | Press release
FREMONT, CA / ACCESS Newswire / October 29, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced the appointment of Vijay Rao to its Board of Directors, effective October 28, 2026. Rao brings 30 years of technology industry experience, including more than 13 years at Meta, where he most recently served as Vice President of Infrastructure. His experience spans infrastructure strategy, AI computing, and semiconductor technologies in hyperscale, enterprise, and startup environments. "Vijay brings deep expertise in infrastructure requirements of hyperscale data centers, including the integration of AI accelerators, high-performance memory, and optical networking," said Gayn Erickson, President and Chief Executive Officer of Aehr Test Systems. "He understands firsthand how semiconductor quality and reliab
U.S. Polo Assn. Executes Early on Europe's Digital Product Passport Mandate29.10.2026 12:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / October 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through some 1,200 U.S. Polo Assn. mono-brand retail stores, numerous branded websites and thousands of other points of distribution worldwide, today announced the brand's early activation of Digital Product Passports (DPPs) across product categories sold into the European Union (EU). As Europe prepares to launch the Digital Product Passport Registry, U.S. Polo Assn. has taken a proactive approach by preparing to deploy DPPs across all products sold into the EU well ahead of the mandatory compliance deadline expected in 2028 or 2029. The global sports brand has already mapped product information for millions of products, creating a scalable framework that will enhance product transparency and support compliance readiness throughout its European operati
LiberNovo Previews Treat Yourself Halloween Flash Sale Across Europe29.10.2026 08:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / October 29, 2026 / LiberNovo is bringing Halloween treats to the desk with its Treat Yourself Halloween Flash Sale, opening October 29 across the European Union and United Kingdom. The event pairs savings of up to 40% on selected Maxis and LiberNovo Omni Pro configurations with limited seasonal gifts for qualifying early shoppers. Spooky extras for your desk Limited Halloween-themed gift packs are available to the first 300 eligible customers in the European Union and the first 100 in the United Kingdom, on a first-come, first-served basis while supplies last. Gift contents, qualifying purchases and availability follow the terms on each regional campaign page. More room for Big and Tall users Maxis is designed around larger frames, with a wider seat and 52 cm seat depth for greater thigh support and room to shift naturally. Maxis Manual provides adjustment by hand. Maxis Electric adds motorised lumbar adjustment and OmniStretch guided back stretching.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom